A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
Karmanos Cancer Institute, Detroit, Michigan University of Minnesota, Minneapolis, Minnesota Roswell Park, Buffalo, New York MD Anderson Cancer Center, Houston, Texas Last updated December 2025